Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71,366,920
-
Total 13F shares
-
64,400,415
-
Share change
-
+12,188
-
Total reported value
-
$231,841,689
-
Put/Call ratio
-
18%
-
Price per share
-
$3.60
-
Number of holders
-
113
-
Value change
-
-$9,805,100
-
Number of buys
-
54
-
Number of sells
-
63
Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q4 2024
As of 31 Dec 2024 C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) had 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 64,400,415 shares of stock of the company.
Largest 10 holders included Soleus Capital Management, L.P., Lynx1 Capital Management LP, WASATCH ADVISORS LP, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, MORGAN STANLEY, VANGUARD GROUP INC, SAMLYN CAPITAL, LLC, and BANK OF AMERICA CORP /DE/.
This table shows 113 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.